ABSTRACT
INTRODUCTION
Mutations in BRAF are present in ~ 50% of metastatic melanomas, 35-60% of advanced thyroid cancers, and in a lower proportion of colorectal, ovarian and lung carcinomas (1) (2) (3) (4) . The small molecule RAF inhibitor vemurafenib (PLX4032, RG7204) has high specificity for the BRAF oncoprotein, and is a potent inhibitor of MAPK signaling and growth of BRAF mutant melanoma cell lines, but not of cancer cell lines with wild-type BRAF (5, 6) . Vemurafenib increases overall survival and progression-free survival in patients with BRAF mutant metastatic melanoma. Although the clinical responses are remarkable, the beneficial effects are not durable, as the median time to progression is 5.3 months (7).
Several mechanisms may account for secondary resistance to PLX4032 in melanomas: e.g. acquisition of RAS mutations, overexpression of PDGFRɴ, expression of a drug-resistant splice variant of BRAF-V600E with enhanced dimerization properties, overexpression of MAP3K8 (COT), among others (8) (9) (10) (11) ). In addition, exposure to HGF from the stromal microenvironment can promote some degree of intrinsic resistance to RAF inhibitors in melanoma cell lines (12, 13). In contrast to the high response rate seen in patients with metastatic melanomas, PLX4032 has limited efficacy as a single agent in patients with BRAF-mutant colorectal cancers (14) . The decreased sensitivity of many colorectal cancer cell lines to growth inhibition by PLX4032 has recently been ascribed to activation of epidermal growth factor receptor (EGFR) signaling (15, 16) . This was proposed to be due to feedback-induced relaxation of the 4 in progress. Here we report that the majority of BRAF-mutant thyroid cancer cell lines are insensitive to the growth inhibitory effects of PLX4032, and that this is largely due to a feedback-induced liganddependent activation of HER2/HER3 signaling. Hence, the early response of BRAF-mutant cancers to selective MAPK pathway inhibitors is marked by the relaxation of oncoprotein-driven negative feedback events, which differ between tumors of various lineages, and which predict a requirement for distinct therapeutic strategies.
RESULTS

Lineage-specific differences in effects of PLX4032 on MAPK signaling and cell growth
BRAF-mutant melanoma cell lines were uniformly sensitive to growth inhibition by PLX4032 (IC 50 < 100 nM), whereas most thyroid (5/6) and colorectal lines (3/4) were comparatively refractory (IC 50 > 1000 nM) (Fig. 1A ). PLX4032 (2 μM) evoked a sustained inhibition in pMEK and pERK in melanoma cell lines through 72 h. By contrast, the inhibition of RAF effectors in BRAF-mutant thyroid and colorectal cell lines was transient, with a rebound beginning 6 h after addition of the drug in 5/6 thyroid and 3/4 colorectal cancer cell lines (Fig. 1B) . The excursions in pERK were consistent with the gene expression kinetics of the ERK phosphatase DUSP5, a component of the transcriptional output driven by MAPK activation (Supplementary Fig. S1A ) (19) . The rebound in pERK was not due to rapid drug metabolism, as readdition of 2 μM PLX4032 72 h after initial exposure did not re-inhibit the pathway (Fig. 1C ), whereas addition of the MEK inhibitor AZD6244 had a potent effect ( Supplementary Fig. S1B ). The rebound in MAPK signaling seen after treatment with PLX4032 likely contributes to attenuate the biological response to RAF inhibition. 
Treatment of thyroid cancer cell lines with RAF inhibitors is associated with RAS activation and increased expression and phosphorylation of RTKs
In cancer cells with mutant BRAF, signaling inputs upstream of the oncoprotein are inhibited by negative feedback (20) . As shown in Fig. 1D , treatment of the thyroid cell line SW1736 with PLX4032 led to a time-dependent increase in GTP-bound RAS, consistent with relaxation of the negative feedback upstream of RAF, which was of a much greater magnitude in thyroid as compared to the SK-Mel-28 melanoma cells. The increase in RAS activity is potentially significant, as enforced RAS activation can overcome the PLX4032-induced block of MAPK in mutant BRAF melanoma cells (8, 21) . We used two different screens to identify potential mediators of these effects. We first obtained gene expression profiles at 0, 1, 6 and 48 h after addition of PLX4032 to SW1736 and SK-MEL-28 cells, and identified several gene clusters with significantly different expression kinetics between the thyroid and melanoma lines ( Supplementary Fig. S2A ). Functional enrichment analysis against the KEGG database revealed overrepresentation of the following terms in SW1736 compared to SK-MEL-28 cells: ErbB signaling pathway, Insulin signaling pathway, Cytokine-cytokine receptor pathway and MAPK signaling pathway ( Supplementary Fig. S2B ). These gene clusters include several RTKs such as HER2, PDGFRβ, EGFR and EPHB2, whose expression differences were confirmed by semiquantitative RT-PCR ( Supplementary Fig.   S2C ).
As an additional screen for receptor tyrosine kinases (RTK) potentially activated in response to the RAF inhibitor in SW1736 cells, we incubated lysates of cells treated with or without 2 μM PLX4032 with human phospho-RTK arrays. Treatment with PLX4032 increased HER3 phosphorylation by > 11-fold, and modestly induced phosphorylation of several members of the ephrin family. There was no detectable increase in EGFR phosphorylation ( Fig. 2A) . Western blots showed induction of total HER2 and HER3, which was associated with a marked increase in HER3 phosphorylation at Y1197 and Y1289 after PLX4032 treatment. This in turn was associated with a rebound in pERK and transient activation of AKT (Fig. 2B) . We next examined whether the changes seen in SW1736 cells were also present in other BRAF mutant cancer cell lines. HER3 phosphorylation was induced in 5/6 thyroid, but was low or undetectable in melanoma and colorectal lines ( Fig. 2C and Supplementary Fig. S3A ). Four of 6 thyroid cancer cell lines showed decreased pEGFR 72 h after vemurafenib, whereas there was no change in colorectal lines ( Fig. 2C and Supplementary Fig. S3A ).
HER2 and HER3 expression and activation were also markedly increased by the allosteric MEK inhibitor PD0325901 6 h post-treatment in thyroid cancers of TPO-Cre/LSL-Braf V600E mice, a genetically accurate model of thyroid tumorigenesis induced by endogenous expression of the oncoprotein (22) (Fig. 2D ).
PLX4032 induces the expression and activation of HER2/HER3 heterodimers in thyroid cancer cells
Thus, following treatment of BRAF-mutant thyroid cancer cells with vemurafenib there is a relief of feedback that results in increased expression of the RTKs HER2 and HER3 and this is associated with RAS activation. HER3 is a kinase-impaired member of the HER family, which is phosphorylated and activated by heterodimerization with one of the other family members (HER2, EGFR or HER4). To identify the HER3 dimer partner we depleted the expression of EGFR or HER2 by RNA interference in 8505C thyroid cells (Fig. 3A) . PLX4032-induced HER3 phosphorylation was inhibited by knockdown of HER2 but not of EGFR. Moreover, co-immunoprecipitation of either HER3 or HER2 resulted in pulldown of the reciprocal partner, confirming the induction of HER2/HER3 complexes by 2 μM PLX4032 in both cell lines (Fig. 3B ).
Of the various HER dimers, the HER2/HER3 heterodimer is considered the most potent signaling unit (23) . The C-terminal residues of these receptors provide docking sites for the adaptor protein GRB2
(HER2>HER3) and the p85 regulatory subunit of PI3Kinase (HER3>HER2). These molecules couple the heterodimer to the RAS/RAF/MAPK and PI3K signaling pathways, respectively (24) . Immunoprecipitation
Research. of HER3 confirmed the recruitment of p85 after PLX4032 treatment (Fig. 3B) . Similarly, IP of either HER3 or HER2 after PLX4032 was associated with increased recruitment of GRB2, likely accounting for the induction of RAS signaling (Fig. 3C) . Moreover, treatment of 8505C cells with the HER kinase inhibitor lapatinib abrogated the PLX4032-induced phosphorylation of HER3, recruitment of p85 to HER3, and the increase in RAS-GTP levels ( Fig. 3D and 3E) . Addition of lapatinib also largely prevented the activation of pAKT and pERK in SW1736 and 8505C cells exposed to the RAF inhibitor (Fig. 3F ).
PLX4032-induced HER2/HER3 activation is dependent on autocrine neuregulin expression and is augmented by exogenous addition of the ligand
Neuregulin-1 (NRG1) is the major HER3 ligand, which promotes its engagement with HER2 kinase and the subsequent transphosphorylation of HER3 (25) . To investigate whether PLX4032-induced activation of HER2/HER3 is mediated by NRG1, we deprived 8505C cells of serum for 24 h in the absence or presence of 2 μM PLX4032. Serum starvation did not entirely shut down the HER3 phosphorylation induced by PLX4032 (Fig. 4A , lane 5 vs 2), pointing to the existence of either a basal level of ligandindependent HER3 activation, or an autocrine production of NRG1. Knock-down of NRG1 markedly inhibited HER3 phosphorylation in cells incubated in serum-free medium, consistent with autocrine secretion of the ligand (Fig. 4B) . Addition of exogenous NRG1 further stimulated HER3 phosphorylation, even in the absence of PLX4032 (Fig. 4A, lanes 3 versus 4) , suggesting that basal co-expression of HER3 and HER2, although low, was sufficient to be efficiently activated by NRG1, and to transduce signaling via AKT and ERK effectors. Addition of NRG1 to PLX4032 pretreated cells superactivated HER3, PI3K and MAPK signaling (lane 6) and this was blocked by 1 μM lapatinib (lane 7). The HER2 antagonist pertuzumab also inhibited signaling in thyroid cancer cell lines exposed to endogenous NRG1 (Fig. 4C ).
Research. Interestingly, expression of NRG1 was consistently higher in BRAF-mutant thyroid than in melanoma or colorectal cell lines ( Fig. 4D and E) . Some melanoma cell lines, such as SK-MEL-28, do show some increase in total HER3 after exposure to PLX4032 ( Supplementary Fig. S4A ), but no HER3 phosphorylation because they do not secrete NRG1. Treatment of SK-MEL-28 cells with exogenous ligand induced HER2/HER3 signaling ( Supplementary Fig. S4B ) and attenuated the growth-inhibitory effects of PLX4032 ( Supplementary Fig. S4C ).
Inhibition of oncogenic BRAF increases HER3 gene transcription
We next examined the mechanisms accounting for the increase in HER3 by MAPK pathway inhibitors in BRAF mutant thyroid cell lines. Upregulation of HER3 has been found to mediate resistance to PI3K/AKT (26) or HER2 (27) inhibitors in HER2-amplified breast cancer cell lines, which is caused in part through a ZFN217 transcription factor and CtBP1/CtBP2 corepressors (28) (29) (30) . CtBPs have also been described to negatively regulate transcriptional activity of the HER3 promoter in breast carcinoma cell lines (30) .
Silencing of CtBP1, and to a lesser extent CtBP2, increased basal HER3 in 8505C cells, and markedly potentiated the effects of PLX4032 (Fig. 5D and 5E ). Knockdown of these factors modestly increased basal and PLX4032-induced HER2 levels, which likely contributes to the remarkable increase in pHER3 we observed ( Fig. 5D and 5E ). Finally, CtBP1 and CtBP2 chromatin immunoprecipitation assays showed decreased binding to the HER3 promoter after treatment with PLX4032 (Fig. 5F ). These findings were confirmed in a second cell line ( Supplementary Fig. S5A ). 
Role of other RTKs in the intrinsic resistance of thyroid cancers to RAF inhibitors
Expression profiling ( Supplementary Fig. S2C ) and the RTK phosphoarray ( Fig. 2A) show that in addition MEK inhibitor AZD6244 suppressed the RAF inhibitor-induced ERK rebound, presumably by interrupting upstream signals mediated by wild-type RAF proteins. There was a more pronounced rebound in ERK compared to MEK phosphorylation after vemurafenib, which may be due to transient downregulation of ERK phosphatases (e.g. DUSP5), in particular at early time points after exposure to the drug.
Two different screening approaches pointed to an increase in the expression and activation of RTKs as primary candidates in mediating the rebound in MAPK activity after treatment with RAF or MEK inhibitors. We focused on HER3 because it showed the greatest magnitude change in phosphorylation in the index line, and because its activation was the most prevalent across all other thyroid lines we tested.
Indeed, both HER3 and HER2 mRNA levels increased ubiquitously in thyroid cancer cells treated with vemurafenib. HER3 is a kinase inactive receptor that requires heterodimerization to transduce signaling.
Co-immunoprecipitation assays and transient knockdown of possible dimer partners led us to identify HER2 as the principal HER3 partner. We did not detect any significant increase in EGFR phosphorylation in response to vemurafenib in any of the thyroid cell lines we tested. EGFR activation has been recently linked to unresponsiveness to MAPK inhibition in BRAF mutant melanoma and colorectal cancer cells (32, 31) . In the latter study, the authors also proposed that the same mechanism likely accounted for the unresponsiveness of thyroid cancer cell lines to RAF inhibitors. This conclusion was based in part on the demonstration that gefitinib enhanced the growth inhibitory effects of PLX4032 in 8505C and BHT101 thyroid cancer cells; however the EGFR-specific monoclonal antibody cetuximab had no effect.
In our hands cetuximab or EGFR knockdown also failed to sensitize thyroid cancer cells to vemurafenib, whereas HER3 or HER2 knockdown had significant growth inhibitory effects. However, HER3 interactions with other ERB family kinases can be promiscuous, suggesting that co-targeting of HER2 and EGFR with kinase inhibitors may be a productive approach to sensitize cells to MAPK pathway inhibition. HER2/HER3 signaling is controlled by HER2-overexpression or ligand binding. As HER2 has no known ligand, the heterodimer is primarily induced by the HER3 ligand NRG1 (24) , which can be produced by tumor cells or by tumor stroma. The importance of tumor production of NRG-1 was recently demonstrated in non-HER2 amplified cancer cells, which were found to be dependent on a NRG1-mediated autocrine loop (34, 35) . These cell lines, mainly from head and neck tumors, showed HER3 expression and phosphorylation and sensitivity to lapatinib (35) . All thyroid cancer cell lines we tested 
MATERIAL AND METHODS
Reagents
PLX4032 and PLX4720 were from Plexxikon and AZD6244 was from AstraZeneca. Lapatinib and imatinib were purchased from Selleck Chemicals. All drugs were dissolved in DMSO for in vitro studies. 
Cell culture
Cancer cell lines were maintained at 37°C and 5% CO 2 in humidified atmosphere and grown in RPMI 1640 or DMEM growth media supplemented with 10% of fetal bovine serum, 2mM glutamine, 50 U/ml penicillin (GIBCO) and 50 μg/ml streptomycin. 
Cell cycle analyses
Cells were plated in triplicate into 60-mm dishes at a density of 1-2. Cells were harvested by trypsinization, washed twice with cold PBS, and lysed in NP-40 buffer (containing 25 ml of 1 M Tris pH 7.4, 15 ml of 5 M NaCl, 20 ml of 1 M NaF, 5 ml of NP-40 and 435 ml of distilled water). Protein concentration was determined using the BCA kit (Thermo Scientific). Western blots were performed on 25 ʅg protein separated by SDS-7.5-10% PAGE using the indicated antibodies.
For immunoprecipitation assays, a volume of 500 ʅl of lysis buffer containing equal amount of proteins was incubated with indicated antibody overnight at 4 °C with gentle rotation. Protein G magnetic beads (Invitrogen) were added for 2 h and washed three times with lysis buffer before suspension in SDSloading buffer. RAS-GTP immuprecipitation was performed using RAS activation assay kit from Millipore according to the manufacturer's protocol. For detection of secreted NRG1, cell media was concentrated using 3K Millipore Amicon Ultra (3K) centrifugal filters at 4000 g for 40 min (35) .
RNA interference
Cells were plated at 20% of confluence in medium without antibiotics and transfected with 5 nM siRNA and Lipofectamine™ RNAiMAX Transfection Reagent (Invitrogen) as indicated in the manufacturer's protocol. SiRNAs for EGFR (#s565), HER2 (#s611), HER3 (#s4779 and #s4780), NRG1 (#s194522), CtBP1 (#s3699), CtBP2 (#s3702) and negative control (#AM4611) were purchased from Ambion.
Phospho-RTK arrays
Human Phospho-RTK arrays were used according to the manufacturer's instructions (R & D Systems).
Briefly, cells were washed with cold PBS and lysed in NP40 lysis buffer with 10% glycerol, and 100 ʅg of lysates was incubated with blocked membranes overnight. Membranes were then washed and exposed to chemiluminescent reagent and then to X-ray film. Quantification of pixels was performed by densitometry using Kodak MI software. 
Animal Studies
Three week-old LSL-Braf/TPO-Cre mice were treated with a single dose of PD0352901 (25 mg/kg).
Thyroids were collected before and 6 h after administering PD352901 and snap frozen in liquid N2.
Proteins were extracted and Western blots performed as described. To test the effects of PLX4720 alone or in combination with lapatinib on tumor growth, 4-6 week-old LSL-Braf/TPO-Cre mice were treated for times a week. Thyroids were collected 6 hours after the final dose of lapatinib, fixed in 4% paraformaldehyde and representative sections stained with Ki67 antibody (Vector Laboratories; 0.05 ʅg/mL).
All procedures were conducted in accordance with the Guidelines for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committees (IACUCs) at Memorial Sloan-Kettering Cancer Center.
Statistical analysis
Statistical significance of differences between the results was assessed using a standard two-tailed t test and Mann-Whitney test for in vivo data, performed using Prism v5.04 (GraphPad Software). p< 0.05 was considered statistically significant.
Data deposition
The microarray data reported in this paper have been deposited in NCBI's Gene Expression Omnibus (GEO) database, www.ncbi.nlm.nih.gov/geo (accession no. GSE37441). 
